Case: 2:13-md-02433-EAS-EPD Doc #: 4078-2 Filed: 07/20/15 Page: 1 of 5 PAGEID #: 71826

P1.71220 N~neteenrhS t NW.Suats a0Waslungton. DC 20036- 2100
. t r ~ . r 202833.8077->. a0211XJ.70n

THE UEI?iERG GROUP INC.
April 29.2003

Jane Brooks
Vice President. Special Initiatives
DuPont de Nemours & Company
Chesmut Run 708
44 17 Lancaster PlkeWilmington. DE 19805
Re:

Pcrfluorooctanoic acid (PFOA)

Dear Ms. Brooks:I am preparing this letter in anticipation of our meeting on April 29,2003 in Washington, DC.
This piece is intended to describe the services THE WEINBERG GROUP INC. can provide
regarding issues related to perfluomhernicals generally and perfluorooctanoic acid (PFOA) inparticular. Please note that this has been prepared prior to our initial meeting. 1 will mostcertainly follow up after our meeting with more specific ideas and recommendations after wehave had the opportunity to discuss DuPont's concerns in greater detail.
The constam theme which permeates our recornmenda:ions on the issues faced by DuPont isthat DUPOhT MUST SHAPE THE DEBATE AT ALL LEVELS. We must implement asuategy at the outset which discourages governmental agencies, the plaintiffs bar. andmisguided environmental groups from pursuing this matter any further than the current risk
assessment contemplated by the Environmental Protection Agency (EPA) and the matter
pending in West Virginia We strive to end this now.
For 23 years. THE WEINBERG GROUP has helped numerous companies manag issues
allegedly related to environmental exposures. Beginning with Agent Orange in 1983, we havesuccessfully guided clients through myriad regulatory. Litigation, and public relations
challenges posed by those whose agenda is to grossly over regulate. extract settlements from.
or otherwise damage the chemical manufacturing industry.
As we understand the situation, there is currently a great deal of attention focused on the safetyof perfluorochemicals generally and PFOA in pmcular. Specifically, due to the situation inWest Virginia and the activities of Environmental Working Group, the threat of expanded

63

Case: 2:13-md-02433-EAS-EPD Doc #: 4078-2 Filed: 07/20/15 Page: 2 of 5 PAGEID #: 71827

P1.7.2Jane Brooks
April 19,2003
Page 2lirieation and additional replation by the EP.4 has become acute. In response to this threat. it
is necessary for DuPont to prepare an overall technical and scientific defense strateu. We canassist with all phases of the technical and scientific defense, but more importantly. shape thedebate and direction of the PFOA issue. The recent ruling by Judge Hill regarding blood
testing underscores the need to act quickly and forcefully. The following will describe some ofour capabilities in assessing che scientific facts, developing appropriate responses or soundscientific messages. building a team of world class experts LOdeliver those messages, andimplementing a strategy to limit the effect of litigation and re ylation on the revenue stream
generated by PFOA.

DEVELOPMEST OF BROAD TECHNICAL DEFENSE STRATEGYFor over two decades, clients have repeatedly communicated to us that of all the services weprovide,.the most valued is our ability to provide an overall science-based defense suategy.
This strategy can be applied to litigation, regulatory, or legislative problems that cause aparticular product to be under pressure. Specifically, during the initial phase of ourengagement by a client, we will harness, focus, and involve the scientific and intellectual
capital of our company with one goal in rnind-creating the outcome our client d e s k s . This
will entail the coordinated and focused compilation of specialists within THE WEINBERGGROUP to receive. review. and analyze all available relevant data regarding PFOA in
particular, and polyfluorochemicals in general. These in-house experts ye scientists andphysicians holding advanced degrees in such areas as epidemiology & biostatistics,pharmacology. pathology. toxicology, oncology. molecular biology. regulatory suategy, andproduct defense.
The outcome of this process will result in the preparation of a multifaceted plan to take controlof the ongoing risk assessment by the EPA, looming regulatory challenges, likely litigation,
and almost certain medical monitoring,hurdles. The primary focus of this endeavor is to suiveto create the climate and conditions that will obviate, or at the very least, minimize ongoing
litigation and contemplated regulation relating to PFOA. This would include facilitating thepublication cf papers and articles dispelling the alleged nexus between PFOA andteratogeniciry as well as other claimed harm. We would also lay the foundation for creating
Daubert precedent to discourage additional lawsuits.
THE WEIhBERG GROUP would also prepare an all-encompassing stravgy to meet public
relations issues and. if necessary, prepare company representaxives for testifying before
governmental bodies. Tacse are but a few of the selvices we provide.
It is also important to note that these services will not be duplicative of the services provided
by law firms and public relations firms. Although we work closely with counsel and otherconsultants. our &rvicts are distinct and science-based.

Case: 2:13-md-02433-EAS-EPD Doc #: 4078-2 Filed: 07/20/15 Page: 3 of 5 PAGEID #: 71828

P1.7.3Jane Brooks
April 29,2003
Page 3
Over the past thirty years. the perfluorochemical industry has amassed a plethora of scientific
data on the safety of PFOA.Many in the indusuy are convinced. wirh good reason. thar PFOAis safe. They would cite numerous studies and conclusions reached by a broad spectrum ofscientists. All of h s is good. and certainly well intended. but the current litigation andregulatory climate demands a fresh new approach. In our opinion. it matters little that theindustry is satisfied PF0.4 is safe.The real issue is the perception outside the industry. This
battle must be won in rhe minds of the regulators, judges, potential jurors, and the plaintiffs
bar. The recent certification by numerous federal courts of medical monitonn_pclasses as wellas the o r p i t a t i o n , sophistication, and ficancial strenzth of the plaintiffs bar require anaggressive, relentless stratew be implemented and dnven by the manufacturen.
Manufacturers must be the aggressors. A defensive posture. in our opinion. would bedisastrous. THE WEINBERG GROUP can help DuPont take the lead on issues related toPFOA. We would suggest a multifaceted approach be implemented immediately.
WHAT W E DO
As the leading scientific consulting fm in the world, THE WEINBERG GROUP serves
industries in four areas, the fmt of which is development, registrarion and support ofpharmaceuticals, biologics, and devices. Other services deal with environrnentd. health andsafety issues through the w of the latest information and techniques establishing risk levels
and risk management techniques and organization of technical functions such as quality
assurance and toxicolo~cal,clinical and epidemiological studies. In the fourth area, we
provide science-based advocacy to help deal with emerging business problems in litigation.
legislation and regulation. Our staff has a broad base of experience supporting counsel andtheir clients in responding to demands for damages. punitive rewards. reimbursement andfuturt medical monitoring costs for personal injury and fraud associated with drugs, corporate
conduct, and failure to provide the corrat information ro the public or legislaton andregulators. Specifically, in the area of Science-Based Advocacy, we assist with:analysis of plaintiffs' best c k and defendants' best response as a tool for strategy
and tactic4 development:
expert witness, spokesperson and panel identification and development in all issues
in litigation;
preparation of counsel for discovery, deposition, negoriation and trial;
records review. analysis. and organization:
preparation of primers describing critical issues and including approaches such asaffidavits for use in summary jud,gnent and opposition to classcertification;
document rcuieval. rnanagernent and analysis:
unique development of experts with chemical, medical, epidemiologcal. biologics,rtgdatory. and legislative backgrounds;
a variety of public relations programs needed to create jury understanding of theissues; andCase: 2:13-md-02433-EAS-EPD Doc #: 4078-2 Filed: 07/20/15 Page: 4 of 5 PAGEID #: 71829

P1.7.4Jane Brooks
April 29. 20C3
Page 4Creation of exhibits. audiovisual presentations. and other devices to enhance layclnderstanding of the issues in dispute. most notably the complex scientificconcepts to be digested in defense argments.
Ours is a task-oriented organization in which clients make specific assipment5 under
carefully planned, client-controlled budgets. Our exper;ence in environmental exposure
matters has repeatedly illustrated our client's need to control as many variables of liability
exposure as possible. In addirion, some preliminary suggestions of tasks for managmg issue
related to PFOA include:
develop "blue ribbon panels" of thought leaders on issues related to PFOA
Lhi RECIOSS WHERE MA.!!UFACTURWG PLANTS ARE LOCATED to createawareness of safety regarding PFOA in areas o i likely litigat~on.and in particularwhere medical monitoring claims may be brought;
develop an a,okressivecampaign focused on the safety and utility of PFOA and theproducts it in whch it is used;
coordinate the retrieval. organization. and analysis of l i t e r a m to date (both internaland external1 regarding safety of PFO.4 and create a centralized searchable databasefor industry use;
begin to identify and retain leading scientists to consult on the range of issues
involving-PFOA so as to develop a premium expert panel and concumntly conflict out
expens from consulting with plaintiffs;
begin to coordinate focus goups of mock jurors to determine the best "themes" fordefense verdicts and perspectives on management of company documents andcompany conduct;rcshapc the debate by identifying the likely known health benefits of PFOA exposureby analyzing existing data, andlor constructing a study to establish not only that PFOA
is safe over a range of serum concentration levels, but that it offers real h d t h benefits(oxygen carrying capacity and prevention of CAD);
coordinate the publishing of white papers on PFOA,junk sciena and the limits ofmedical monitoring;work with industry lobbyists to ensure they remain on message regarding the scientificissues relaled to PFOA;
provide the strategy to illustrate how epidemiological association has little or nothing
to do with individual causation. and:begin to shape the Dauben standards in ways most beneficial to manufactures.

THE W E I N E R G GROUP has developed an understanding of the variety of approaches
needed to deal with each of these issues. Indeed, we have trial experience in these issues aswell.

Case: 2:13-md-02433-EAS-EPD Doc #: 4078-2 Filed: 07/20/15 Page: 5 of 5 PAGEID #: 71830

P1.7.5sJane Brooks
April 29,2003
Page 3I want to reiterate that we already have extensive experience in helping a Fortune 40 clientwith a very sirmlar compound to PFOA. Our experience and knowledge regarding thiscompound is very we11 established. We do not need ro educate ourselves at DuPont's expensc.
I again stress that this was prepared prior to our initial meeting. but I wanted co provide
marerial for you ro ruminate upon before our next discussion on these issues. Thank you again
for the opportunity to be of service.
Sincerely,

Vice President
Product Defense
THE WEINBERG GROUP INC.